^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Clear Cell Renal Cell Carcinoma |
| Drug: | Bavencio (avelumab) (PD-L1 inhibitor) + Inlyta (axitinib) (VEGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
First-line therapy for clear cell histology: Other recommended regimens…Axitinib + Avelumab
